{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:14:55Z","timestamp":1778944495806,"version":"3.51.4"},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,12,15]]},"DOI":"10.2169\/internalmedicine.3406-19","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T22:03:08Z","timestamp":1565042588000},"page":"3583-3587","source":"Crossref","is-referenced-by-count":16,"title":["A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab"],"prefix":"10.2169","volume":"58","author":[{"given":"Mizuho","family":"Nara","sequence":"first","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumito","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Komatsuda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Wakui","sequence":"additional","affiliation":[{"name":"Department of Life Science, Akita University Graduate School of Engineering Science, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 27: 277-301, 1951."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Greco A, Rizzo MI, De Virgillio A, et al. Churg-Strauss syndrome. Autoimmun Rev 14: 341-348, 2015.","DOI":"10.1016\/j.autrev.2014.12.004"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33: 1094-1100, 1990.","DOI":"10.1002\/art.1780330806"},{"key":"4","unstructured":"4. Jennette JC, Falk RJ, Bacon N, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65: 1-11, 2013."},{"key":"5","unstructured":"5. Wu EY, Hernandez ML, Jennette JC, Falk JF. Eosinophilic granulomatosis with polyangiitis: clinical pathology conference and review. J Allergy Clin Immunol Pract 6: 1496-1504, 2018."},{"key":"6","unstructured":"6. Navarro-Mendoza EP, Tob\u00f3n GJ. Eosinophilic granulomatosis with polyangiitis: newer therapies. Curr Rheumatol Rep 20: 23, 2018."},{"key":"7","unstructured":"7. Raffray L, Guillevin L. Treatment of eosinophilic granulomatosis with polyangiitis: a review. Drugs 78: 809-821, 2018."},{"key":"8","unstructured":"8. Gendelman S, Zeft A, Spalding SJ. Childhood-onset eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): a contemporary single-center cohort. J Rheumatol 40: 929-935, 2013."},{"key":"9","unstructured":"9. Eleftheriou D, Gale H, Pilkington C, Fenton M, Sebire NJ, Brogan PA. Eosinophilic granulomatosis with polyangiitis in childhood: retrospective experience from a tertiary referral centre in the UK. Rheumatology (Oxford) 55: 1263-1272, 2016."},{"key":"10","unstructured":"10. Fina A, Dubus JC, Tran A, et al. Eosinophilic granulomatosis with polyangiitis in children: data from the French RespiRare<sup>\u00ae<\/sup> cohort. Pedistr Pulmonol 53: 1640-1650, 2018."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sada KE, Yamamura M, Harigai M, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 16: R101, 2014.","DOI":"10.1186\/ar4550"},{"key":"12","unstructured":"12. Iglesias E, Camacho Lovillo M, Delgado Pecell\u00edn I, et al. Successful management of Churg-Strauss syndrome using omalizumab as adjuvant immunomodulatory therapy: first documented pediatric case. Pediatr Pulmonol 49: E78-E81, 2014."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Aguirre-Valencia D, Posso-Osorio I, Bravo JC, Bonilla-Abad\u00eda F, Tob\u00f3n GJ, Ca\u00f1as CA. Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Clin Rheumatol 36: 2159-2162, 2017.","DOI":"10.1007\/s10067-017-3780-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Leroy C, Rigot JM, Leroy M, et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis 10: 136, 2015.","DOI":"10.1186\/s13023-015-0332-8"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380: 651-659, 2012.","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"16","unstructured":"16. Gioffredi A, Maritati F, Oliva E, Buzio C. Eosinophilic granulomatosis with polyangiitis: an overview. Front Immunol 5: 549, 2014."},{"key":"17","unstructured":"17. Khoury P, Grayson PC, Klion AD. Eosinophils in vasculitis: characteristic and roles in pathogenesis. Nat Rev Rheumatol 10: 474-483, 2014."},{"key":"18","unstructured":"18. Yanagibashi T, Satoh M, Nagai Y, Koike M, Takatsu K. Allergic diseases: from bench to clinic - contribution of the discovery of interleukin-5. Cytokine 98: 59-70, 2017."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Jakiela B, Szczeklik W, Plutecka H, et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. Rheumatology (Oxford) 51: 1887-1893, 2012.","DOI":"10.1093\/rheumatology\/kes171"},{"key":"20","unstructured":"20. Bagnasco D, Ferrando M, Varricchi G, et al. Anti-interleukin 5 (IL-5) and IL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma. Front Med (Lausanne) 4: 135, 2017."},{"key":"21","unstructured":"21. Faverio P, Bonaiti G, Bini F, Vaghi A, Pesci A. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy. Ther Clin Risk Manag 14: 2385-2396, 2018."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. New Engl J Med 376: 1921-1932, 2017.","DOI":"10.1056\/NEJMoa1702079"},{"key":"23","unstructured":"23. Varricchi G, Bagnasco D, Ferrando M, et al. Mepolizumab in the treatment of severe eosinophilic asthma in adults: current evidence and practical experience. Ther Adv Respir Dis 11: 40-45, 2017."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Pradhan RR, Nepal G, Mandel S. Safety and efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis. Pulm Med 2019: 4376380, 2019.","DOI":"10.1155\/2019\/4376380"},{"key":"25","unstructured":"25. Faverio P, Bonaiti G, Bini F, Vaghi A, Pesci A. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy. Ther Clin Risk Manag 14: 2385-2396, 2018."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Schwarz C, M\u00fcller T, Lau S, Parasher K, Staab D, Wahn U. Mepolizumab a novel option for the treatment of hypereosinophilic syndrome in childhood. Pediatr Allergy Immunol 29: 28-33, 2018.","DOI":"10.1111\/pai.12809"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/24\/58_3406-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T03:42:14Z","timestamp":1576899734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/24\/58_3406-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,15]]},"references-count":26,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3406-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,15]]}}}